The 14 analysts offering 12-month price forecasts for Intellia Therapeutics Inc have a median target of 80.00, with a high estimate of 111.00 and a low estimate of 22.00. The median estimate represents a +16.98% increase from the last price of 68.39.
The current consensus among 15 polled investment analysts is to Buy stock in Intellia Therapeutics Inc. This rating has held steady since March, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.67
Reporting Date May 04
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.